Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia
Naval Daver, Aditi Shastri, Tapan Kadia, Kate Newberry, Naveen Pemmaraju, Elias Jabbour, Linghsa Zhou, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek, Naval Daver, Aditi Shastri, Tapan Kadia, Kate Newberry, Naveen Pemmaraju, Elias Jabbour, Linghsa Zhou, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek
Abstract
We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL). Patients (n = 29; 18 RBC-transfusion dependent) received 0.5mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.
Keywords: Anemia; Myelofibrosis; Pomalidomide.
Published by Elsevier Ltd.
Source: PubMed